RESEARCH PAPER

# The prognosis of functional (psychogenic) motor symptoms: a systematic review

Jeannette Gelauff, 1 Jon Stone, 1 Mark Edwards, 3 Alan Carson 2

► Additional material is published online only. To view please visit the journal online http://dx.doi.org/10.1136/ jnnp-2013-305321).

<sup>1</sup>Department of Clinical Neurosciences, University of Edinburgh, Edinburgh, UK <sup>2</sup>Department of Psychiatry, University of Edinburgh, Edinburgh, UK <sup>3</sup>Institute of Neurology, London, UK

#### Correspondence to

Dr J Stone, Department of Clinical Neurosciences, Western General Hospital, Edinburgh EH4 2XU, UK; Jon.Stone@ed.ac.uk

Received 15 March 2013 Revised 9 August 2013 Accepted 20 August 2013 Published Online First 12 September 2013

**ABSTRACT Background** The prognosis of functional (or psychogenic) motor symptoms (weakness and movement disorder) has not been systematically reviewed. Methods We systematically reviewed PubMed for all studies of eight or more patients with functional motor symptoms reporting follow-up data longer than 6 months (excluding studies reporting specific treatments). We recorded symptom duration, physical and psychiatric comorbidity, disability, occupational functioning at follow-up and prognostic factors. **Results** 24 studies were included. There was heterogeneity regarding study size (number of patients (n)=10 491), follow-up duration clinical setting and data availability. Most studies (n=15) were retrospective. Reported symptom outcome was highly variable. Mean weighted follow-up duration was 7.4 years (in 13 studies where data was extractable). The mean percentage of patients same or worse at follow-up for all studies was 39%, range 10% to 90%, n=1134. Levels of physical disability and psychological comorbidity at follow-up were high. Short duration of symptoms, early diagnosis and high satisfaction with care predicted positive outcome in two studies. Gender had no effect. Delayed diagnosis and personality disorder were negatively correlated with outcome. Prognostic factors that varied between studies included age, comorbid anxiety and depression, IQ, educational status, marital status and pending litigation.

**Conclusions** Existing follow-up studies of functional motor symptoms give us some insights regarding outcome and prognostic factors but are limited by their largely retrospective and selective nature. Overall, prognosis appears unfavourable. The severity and chronicity of functional motor symptoms argues for larger prospective studies including multiple prognostic factors at baseline in order to better understand their natural history.

# INTRODUCTION

Functional (or psychogenic) motor symptoms refer to weakness or movement disorders that are genuine but do not relate to an underlying neurological disease. 1 2 Alternative names for this group of symptoms include motor conversion disorder/ symptoms (diagnostic and statistical manual of mental disorders, fourth version (DSM IV)) and dissociative motor disorder (ICD-10). Functional motor symptoms, as we will call them in this review, are the second commonest 'non-organic' symptom seen in neurological practice after non-epileptic attacks,<sup>3</sup> <sup>4</sup> with paralysis or weakness being the commonest manifestation.<sup>3</sup>

The perception of the prognosis of functional motor symptoms in the medical literature is variable. Historically, patients with acute functional motor symptoms have often been thought to have a good outcome. However, neurologists working in specialist clinics frequently encounter patients with disabling and chronic functional motor symptoms that appear resistant to treatment.

We aimed to systematically review all follow-up studies of functional motor symptoms. We focused on global clinical outcome as well as physical and occupational functioning. We also collated data regarding negative and positive prognostic factors including comorbidity and socio-economic status.

The issue of diagnostic revision and misdiagnosis at follow-up was not included in this review since we have systematically reviewed this topic previously.<sup>5</sup>

A broad search strategy was used, using PubMed, the reference lists of articles we found in this search and reference lists of important overview articles, as well as articles known by JS, MJE and AC.

We searched for all studies reporting on functional motor symptoms, using these terms: "conversion disorder, conversion symptoms, hysteri\*, somatisation, psychogenic, psychosomatic, nonorganic, unexplained, dissoc\*" and first "weakness, paralysis, movement disorder, gait disorder, motor symptoms, dystonia, myoclon\*, tremor, twitching, wheelchair, \*plegia, \*paresis, disability, \*" and second "prognosis", "follow-up", "natural history" and "natural course". Relevant studies were identified and their reference lists were hand searched.

Inclusion and exclusion criteria are listed in table 1. We attempted to find all the literatures from 1 January 1940 up to and including 1 January 2013.

We extracted information on: number, age and gender of participants; follow-up duration and proportion followed up; study design; symptom duration and type; prognostic factors: physical and psychiatric comorbidity, disability and occupational functioning at follow-up. We planned an analysis with a general composite of outcome and of outcome per symptom. We planned graphical analyses of prognosis by duration of follow-up, duration of symptoms at initial presentation, type of motor symptom, age and proportion of patients followed up in each study. Prognostic factors were divided into: 'positive', 'negative' and 'no influence' for the purpose of description and analysis.

# **RESULTS**

The initial search strategy yielded 5874 articles. After deduplication and review of titles and

To cite: Gelauff J. Stone J. Edwards M. et al. J Neurol Neurosurg Psychiatry 2014;85:220-226.

Table 1 Criteria for study inclusion and exclusion					
Inclusion criteria	Exclusion criteria				
Definition of symptoms that clearly indicates symptoms were not due to a disease process	Hysteria defined as anxiety disorder or hysterical personality				
Motor symptoms are at least 50% of reported cases	Symptoms not specified				
Mean follow-up period ≥6 months	Studies whose explicit purpose was the description of a treatment intervention				
A report of clinical outcome	Follow-up only focused on misdiagnosis				
Article in English	Only abstract available				
Number of patients ≥8	Fatigue without specific description of limb weakness or movement disorder				
Adult study					

references, 102 studies were selected for the review as potentially eligible, 78 studies were excluded. Finally, 24 articles were included. Table 2 summarises all included articles and the outcome reported. Six of the excluded articles had useful information about prognosis and are also described separately below but were not included in the main analysis.<sup>6–11</sup>

### Included studies (24 studies, n=2069)

There was considerable heterogeneity between studies with studies ranging in size (n=8–517), duration of follow-up (0.5–19 years), completeness of follow-up (14–100%), type of motor symptom, symptom outcome (ranging from 10 to 90% better or completely recovered at follow-up) and data availability of the studies. Most studies (n=15) were retrospective. There were two pairs of studies of dystonia<sup>12</sup> <sup>13</sup> and tremor<sup>14</sup> <sup>15</sup> in which the population studied overlapped. The study of Carter<sup>16</sup> was considered as two separate prognostic studies of paralysis and tremor. There was one case–control study, which was prospective, <sup>13</sup> but there were no prognostic studies in which control data were used to determine prognostic factors.

#### **Outcome**

Typically, the outcome for patients with functional motor symptoms was unfavourable. In four out of 22 studies (not including two overlapping studies), <sup>12</sup> <sup>14</sup> 66% to 100% of patients had the same or worse symptoms at follow-up (n=135). <sup>13</sup> <sup>17-19</sup> In further 14 studies, 33% to 66% of patients' symptoms were the same or worse at follow-up (n=533), <sup>15</sup> <sup>16</sup> <sup>20-31</sup> and in only five studies, 33% or less of patients had symptoms same or worse at follow-up (n=464). <sup>16</sup> <sup>32-35</sup> Table 3 shows the percentages of symptoms that were same or worse, or improved or remitted at follow-up, weighted according to the numbers of patients in follow-up, in the above-mentioned categories.

The mean weighted duration of follow-up in years was 7.4 years (in 13 studies where mean years of follow-up data were extractable). Carrying out an analysis of the total 23 studies weighted according to the numbers of patients at follow-up but not heterogeneity and duration of follow-up, the mean percentage with the same or worse outcome overall was 40% (n=1134) with outcome for each symptom being dystonia 69% (n=77), tremor 66% (n=67), Mixed Movement Disorders 44% (n=291), Weakness 41% (n=129), Mixed Motor 29% (n=556). The total percentage of patients whose symptoms completely remitted was 21.5%, excluding five studies that did not mention numbers of total remission. 19 22 28 29 35

#### Physical and occupational functioning

Generally, high levels of dependency, disability and work absence were found at follow-up. A range of 17% to 65% of patients were at work at follow-up (n=734). <sup>15</sup> <sup>18–20</sup> <sup>23</sup> <sup>27</sup> <sup>32</sup> <sup>34</sup> <sup>35</sup>

## Comorbidity

High frequencies of comorbid functional (psychogenic) symptoms were seen at baseline and follow-up. None of the studies reported data comparing these comorbidities at follow-up and baseline. In four studies (n=188),<sup>13</sup> <sup>17</sup> <sup>19</sup> <sup>22</sup> 30% to 60% of patients and in another three studies (n=216) 60% to 90% of patients had one or more other functional neurological symptom. <sup>14</sup> <sup>20</sup> <sup>28</sup> Often more than one symptom at a time was reported, especially pain in multiple sites (eg, back, head, limbs), sensory symptoms, as well as many others such as bladder or bowel symptoms, fatigue, nausea, diarrhoea, sleep problems, dizziness, non-epileptic seizures, memory problems, visual disturbance, speech problems, black outs, dysphonia and hearing problems. A supplementary study<sup>36</sup> to the included study by Crimlisk *et al*<sup>20</sup> highlighted frequent re-referrals to neurology and other medical specialties during the follow-up period.

Psychiatric comorbidity was also seen frequently. Mostly anxiety and depression were reported, anxiety in 17% to 42% of patients in five studies (n=266),  $^2$   $^{13}$   $^{25}$   $^{27}$   $^{32}$  depression (or affective disorder) 19% to 71% in six studies (n=349).  $^{13}$   $^{15}$   $^{19}$   $^{27}$   $^{32}$  Dissociative symptoms and personality disorder were also commented on.  $^{13}$   $^{25}$   $^{32}$ 

Additional neurological disease comorbidity at presentation was reported in Feinstein  $et\ al^{27}$  in 12% (not further specified), in Kim  $et\ al^{17}$  17%, of which mainly organic tremor, and furthermore dystonia, dyskinesia and Parkinson's disease, each in one patient and in Crimlisk  $et\ al.^{20}$ 

# Analysis of improvement by study duration, % follow-up and symptom

Figure 1 shows symptom outcome plotted against duration of follow-up. There was no obvious relation between follow-up duration and outcome, nor, perhaps surprisingly between symptom type and symptom outcome. Figure 2 shows symptom outcome plotted against the follow-up rate of individual studies. There was possibly a slight trend indicating that a higher follow-up rate might be correlated with a better mean outcome, but a wide spread, different study size and other confounding factors prevent any firm conclusions. Figure 3 shows symptom outcome plotted against mean age of patients in the study with no clear trend seen. We also carried out an analysis of outcome relative to symptom duration prior to recruitment to the study. There were only 11 studies with extractable data. No clear trend emerged from this analysis (see online supplementary file 1).

# Outcome by type of motor symptom

Prognosis varied between different functional motor symptoms. Studies of functional tremor showed relatively high proportions of patients same or worse at follow-up (44–90%) (n=191). <sup>14</sup> <sup>16</sup> <sup>17</sup> <sup>22</sup> <sup>23</sup> Functional/psychogenic dystonia had an even worse prognosis. In the overlapping studies of Schrag *et al* <sup>13</sup> and Ibrahim *et al* <sup>12</sup> (n=103) with a mean of 4.9 years and 7.6 years of follow-up 73% to 78% of patients had the same or worse symptoms. The outcome of weakness/paralysis was more variable, ranging from 4% to 69% of patients with same or worse symptoms at follow-up (n=25–60). <sup>16</sup> <sup>19</sup> <sup>28</sup> <sup>33</sup> <sup>34</sup> The most optimistic study in this group was a 1949 study in which patients were treated actively with hypnosis, thiopental suggestion and

Table 2 Study characteristics and outcome

Article characteristics						Symptom outcome				Disability/functioning			
Author (year)	Symptom	N	Follow-up duration	Follow-up rate (%)	Mean age	Design	% <b>F</b>	Worse (%)	Same (%)	Improved (%)	Complete remission (%)	Disability %	Work %
McKeon (2009) <sup>22</sup>	Tremor	62	3.2 years	53	50°	R	70	64		36		40% severe, 24% moderate, 36% mild	-
Jankovic (2006)*14	Tremor	211	3.4 years	60	44 <sup>b</sup>	R	73	43		57	_	-	-
Kim (1999) <sup>17</sup>	Tremor	70	1.5 years	14	41 <sup>b</sup>	R	66	30	60	10	0	-	_
Deuschl (1998) <sup>23</sup>	Tremor	25	0.5–8 years	64	42 <sup>b</sup>	Р	80	25	38	-	37	If symptoms remained: 75% mod and 25% severely impaired daily	44% retired
Carter (1949) <sup>16</sup>	Tremor	10	4-6 years	80	-	?	-	0	50	0	50	_	_
Schrag (2004) <sup>13</sup> **	Fixed dystonia	103	3.3 years	67	30 <sup>b</sup>	P+R	83	73		19	8	all on allowance	
Ibrahim (2009) <sup>12</sup> **	Fixed dystonia	41	7.6 years	73	43 <sup>b</sup>	Р	83	31	46	23	0		_
Lang (1995) <sup>24</sup>	Dystonia	18	?	44	35,5°	R	72	0	37	38	25		
Lang (1995) <sup>18</sup>	Parkinsonism	14	?	100	43°	R	50	0	79	7	14	7% moderate, 57% heavy, 36% fully disabled	79% unable to work, 14% early retired, 7% unemployed
Munhoz (2011) <sup>25</sup>	Mixed mov dis	83	0.5 years	70	39°	Р	88	40		22	38	-	<del>-</del>
Ertan (2009) <sup>26</sup>	Mixed mov dis	49	15d-2 years	53	7–70°	Р	70	_	_	46	_	_	_
Thomas (2006) <sup>15</sup> *	Mixed mov dis	517	3.4 years	24	43 <sup>b</sup>	R	73	22	21	57	0		33% employed, 30% on disability, 4% unemployed
Feinstein (2001) <sup>27</sup>	Mixed mov dis	88	3.2 years	48	45 <sup>b</sup>	R	62	33	24	33	10	_	17% at work, 76% unemployed
Williams (1995) <sup>32</sup>	Mixed mov dis	24	1.8 years	88	36,5 onset	R	79	14		57	29	27% disabled	27% at work
Factor (1995) <sup>21</sup>	Mixed mov dis	28	0-6 years	71	51 <sup>u</sup>	R	60	50		0	50	_	_
Stone (2003) <sup>19</sup>	Weakness	60	12.5 years	70	36 <sup>b</sup>	R	81	69		31		38% limited in moderate activities	30% disability leave
Binzer (1998) <sup>34</sup>	Weakness	35	3.5 years	86	39°	Р	60	10		27	63	-	57% at work
Knutsson (1985) <sup>28</sup>	Weakness	25	0.5–9 years	100	19–47 <sup>u</sup>	R	76	0	56	44		_	_
Brown (1954) <sup>33</sup>	Weakness	11	1–6 years	91	26 <sup>b</sup>	?	10	10	20	20	50		
Carter (1949) <sup>16</sup>	Weakness	23	4–6 years	96	-	?	-	4	14	4	78		
Crimlisk (1998) <sup>20</sup>	Mixed motor	73	5–7 years	88	37 <sup>b</sup>	R	48	38	14	20	28	-	33% at work, 47% health related retirement
Mace (1996) <sup>29</sup> ***	Mixed motor	31	9.8 years	?		R	78	44		56			
Couprie (1995) <sup>30</sup>	Mixed motor	60	4.5 years (median)	93	36 <sup>b</sup> (median)	R	64	43		16	41	34% small restrictions in lifestyle to severely impaired independence, 7% total dependence	
Gatfield (1962) <sup>31</sup>	Mixed motor	37	2.5-10 years	65	14–67 <sup>b</sup>	Р	83	62		-	38		
Ljungberg (1957) <sup>35</sup>	Mixed motor	381	11.9 years	?	28,5°	Р	65	0	20	80			65% at work, 14% health related pension

Neuropsychiatry

Symptom Weakness, functional paralysis/paresis; mixed mov dis, more than one type of movement disorder; mixed motor, mixture of hyperkinetic and movement disorder and weakness/paralysis. Age: bean age at baseline, eman age at onset of symptoms, "Unclear. %F= percentage females, symptom outcome in percentages. \*overlapping studies, \*\*overlapping studies, \*\* mixed study of sensory and motor symptoms, follow-up rate and total amount of patients with motor symptoms in follow-up unclear.

d, days; N, number of patients at baseline; P, prospective; R, retrospective.

Table 3 Percentages of symptoms that were same/worse or improved/remitted at follow-up, weighted according to the number of patients in follow-up and categorised by symptoms same/worse per study

Symptoms same or worse at follow-up (%)	Number of studies	Total n in follow-up	% Same/worse symptoms (weighted)	% Improved/remitted symptoms (weighted)
<33	5	464	19	81
33–66	14	533	49	51
>66	4	135	74	26
				•

Categories <33% symptoms same/worse, 33% to 66% of symptoms same/worse, >66% of patients same/worse.

psychotherapy.<sup>16</sup> The 1957 study of Ljungberg (n=381) still represents one of the best prospective studies and contained a comparison of outcome between symptoms.<sup>35</sup> In this study, patients with gait disorder fared better at 5 years (10% symptomatic) compared to patients with weakness (32% symptomatic) and tremor (51%). Two studies looked at influence of symptom type on outcome within their sample and found no correlation.<sup>27</sup> <sup>32</sup>

# **Prognostic factors**

Factors correlated with outcome and therefore thought to influence prognosis were investigated in many studies. Table 4 shows these factors.

### Age

Four studies (n=211) found that younger age predicted a better outcome, <sup>15</sup> <sup>19</sup> <sup>23</sup> <sup>29</sup> but seven studies (n=248) found age was not a significant prognostic factor. <sup>12</sup> <sup>20</sup> <sup>27</sup> <sup>30</sup> <sup>32</sup> <sup>34</sup> <sup>35</sup>

#### Gender

None of the studies that looked at the influence of gender on outcome found an effect (n=676). <sup>12 15 19 20 32 34 35</sup>

# Duration of symptoms prior to diagnosis


A shorter duration of symptoms prior to diagnosis was shown to predict a better outcome in nine studies (n=451). <sup>15</sup> <sup>20-22</sup> <sup>25</sup> <sup>27-30</sup> There were no studies which did not find a relationship between duration of symptoms prior to diagnosis and outcome, suggesting this as one of the most consistent findings of this review.

#### Psychiatric comorbidity

The presence of psychiatric comorbidities was correlated with outcome in eight studies. 12 14 15 20 27 29 34 35 Six found a negative effect on outcome (n=633). 12 14 27 29 34 35 Ibrahim *et al* 12 found a high Hospital Anxiety and Depression Scale (HADS) score was correlated with bad outcome, Mace and Trimble found anxiety had a worse effect than depression, Feinstein *et al* 27 found the severity of psychiatric comorbidity influenced outcome. Jankovic *et al* 14 reported that any psychological, psychogenic or somatic comorbidity predicted negative outcome. Binzer *et al*, 34 however, did not find any correlation between an axis I diagnosis and outcome. Personality disorder was negatively correlated with outcome in three studies (n=442). 29 34 35 Two studies reported a positive effect of the presence of an affective or anxiety disorder on outcome. The authors of these studies suggested that functional symptoms improved synergistically with these emotional disorders.


# Education, IQ, social class, marital status and litigation

Several studies found educational status (n=93),<sup>27</sup> <sup>32</sup> <sup>34</sup> IQ (n=381)<sup>35</sup> and social class (n=64)<sup>20</sup> and had no prognostic effect. The effect of marital status was investigated in two studies (n=106), one showing no effect,<sup>27</sup> while the other found that change in marital status (either marriage or separation) was positively correlated with outcome.<sup>20</sup> Two overlapping studies reported on the effect of perception of the patient's social life, one found it beneficial (n=122,<sup>15</sup> the other found no effect (n=127).<sup>14</sup> Pending litigation correlated with negative outcome in one study (n=64), <sup>20</sup> while three (partially



**Figure 1** Proportion 'same or worse symptoms' at follow-up relative to mean follow-up duration in years in all included studies, also showing symptom. Tremor, Dystonia (functional dystonia and fixed dystonia), Mixed movement disorders (more than one type of movement disorder), Weakness (paralysis), Mixed weakness and movement disorders (mixture of movement disorder and weakness/paralysis). Two studies did not record follow-up duration. <sup>18</sup> <sup>24</sup>

# Neuropsychiatry



**Figure 2** Proportion 'same or worse symptoms' at follow-up relative to follow-up rate in 23 included studies. One study did not record percentage follow-up.<sup>29</sup>

overlapping) studies (n=164) did not find a correlation. 14 15 27 No other studies reported on litigation.

#### Confidence in clinician and explanation


'Patient confidence in the clinician and the proposed explanation and treatment' were positively correlated with outcome in two overlapping studies. <sup>14</sup> <sup>15</sup>

## Treatments given as part of the study

In many of the studies included in this review, some treatment was given in part of the population. 13-18 21 25 32 Treatment interventions were very heterogeneous, ranging from antidepressants and levodopa to hypnosis, suggestion and psychological treatment. Results were usually only partially helpful in some of the patients or gave temporary relief. Crude analysis of the weighted percentage of same or worse symptoms at follow-up according to the number of patients at follow-up in these studies was 49%. All other (non-treatment) studies had a weighted percentage of same or worse symptoms at follow-up according to the number of patients at follow-up of 39%. We did not find a relation between better outcome and treatment interventions.

# Additional excluded studies

Six studies described some form of follow-up on cohorts of patients with functional motor symptoms but did not meet



**Figure 3** Proportion 'same or worse symptoms' at follow-up relative to mean age in 19 included studies. Studies that reported age at onset of symptoms are depicted with a slightly bigger black circle; studies that reported age at baseline of the study are depicted with a grey circle. Studies that did not record mean age, <sup>29</sup> or whether age was recorded at baseline or follow-up, <sup>16</sup> <sup>21</sup> <sup>28</sup> are not shown.

inclusion criteria for our main review, primarily because the follow-up duration was too short or not stated (see online supplementary table S1). <sup>6-11</sup> In three studies (total n=74), inpatients in spinal rehabilitation units with functional paralysis were reported with data at discharge. <sup>7 9 11</sup> The outcome was 100% recovery in two of these studies <sup>9 11</sup> and 55% in another. <sup>7</sup> In some follow-up studies of functional movement disorder, that outcome was more variable although duration was unknown. <sup>6 8 10</sup>

# DISCUSSION Outcome

Overall, the prognosis of functional motor symptoms appears unfavourable. In a large majority of studies (20 out of 24 studies), more than one-third of patients had the same or worse symptoms at follow-up. In cases where symptoms improved, they tended not to resolve completely.

The outcome of motor symptoms appears comparable to a recent review of the prognosis non-epileptic attacks, which found in a majority of studies that 60% or more patients were still having attacks at follow-up,<sup>37</sup> and to a study of a more general group of 761 patients with symptoms unexplained by disease attending neurology clinics (Scottish Neurological Symptom Study, SNSS) where poor outcome was reported by 67%.<sup>38</sup>

High rates of physical and psychological comorbidity at baseline in these studies highlight the importance of not simply considering functional motor symptoms in isolation. They are typically only one of multiple somatic and psychological symptoms. In most studies, levels of physical disability were high, and working status and quality of life impaired. Studies examining comparator groups of disease controls have found comparable levels of disability and quality of life between patients with functional movement disorders and Parkinson's disease, <sup>39</sup> and between functional paralysis and multiple sclerosis. <sup>19</sup> SNSS found that patients with symptoms unexplained by disease had comparable rates of physical disability and higher rates of psychological disability to patients with defined neurological disease. <sup>40</sup>

Movement disorders, like fixed dystonia and tremor, seem to have a worse outcome than weakness and paralysis. Because of the low number of studies and the multiple confounding factors varying between studies, it is difficult even to draw this conclusion. In particular, studies of patients with movement disorders are often drawn from specialist movement disorder clinics where severity may be worse, in comparison with studies of patients with weakness which have more commonly been drawn from a general neurology setting.

#### **Prognostic factors**

We found heterogeneity in many prognostic factors reported. Probably the strongest factor to emerge was a short duration of symptoms as a good prognostic factor. Even here, clinical experience indicates that a long duration of symptoms does not always preclude a good recovery and similarly patients with short duration of symptoms do not always recover.

The influence of age was surprisingly ambiguous, and there was no clear effect from gender or even comorbid emotional disorder. We did not include paediatric studies which generally do report better outcomes.<sup>37</sup> <sup>41–44</sup>

Socio-economic factors, such as a change in marital status may be a good prognostic factor, but there was surprisingly no effect with litigation, although only four studies looked at this. In contrast, the receipt of health-related financial benefits was a strong independent predictor of poor outcome in the SNSS.<sup>38</sup>

Author	Symptom	Positive	Negative	No effect*
McKeon <sup>22</sup>	Tremor	Early diagnosis	_	Initial diagnostic certainty
Jankovic <sup>14</sup>	Tremor	Patient compliance with and confidence in a positive treatment outcome	precipitating event, psychiatric comorbidity	Duration, smoking, litigation, neurol/other comorbidity, family history, low social life perception, seeing other therapists, somatisation
Deuschl <sup>23</sup>	Tremor	Young age	_	-
Ibrahim <sup>12</sup>	Fixed dystonia	- ' '	Complex Regional Pain Syndrome at baseline, higher Hospital Anxiety and Depression Score (HADS) scale	Age, gender, duration, somatoform disorder at baseline
Munhoz <sup>25</sup>	Mov dis	Early diagnosis	_	_
Thomas <sup>15</sup>	Mov dis	Early diagnosis, younger age, confidence in positive outcome of treatment, strong physical health, positive perception of social life, anxiety	-	Gender, poor social life perception, history of abuse, litigation, dependence
Feinstein <sup>27</sup>	Mov dis	Sudden onset	long duration prior to diagnosis; extent of psychiatric comorbidity	Age, marital status, education, employment, litigation, type of movement disorder
Williams <sup>32</sup>	Mov dis	-	-	age, gender, education, chronicity, type of movement disorder
Factor <sup>21</sup>	Mov dis	Early diagnosis	_	_
Stone <sup>19</sup>	Weakness	Sensory symptoms better than weakness	Higher age at onset	Gender
Binzer <sup>34</sup>	Weakness	high global functioning score (axis V)	High Beck Hopelessness Scale, axis III diagnosis, personality disorder, cluster C personality score (anxious or fearful personality disorders), low global index functioning score	Age, gender, degree of disability, educational status, axis I disorder, depression, illness behaviour, locus of control score, memories of childhood experience
Knutsson <sup>28</sup>	Weakness	Early diagnosis, short hospital stay	_	_
Crimlisk <sup>20</sup>	Motor	Early diagnosis, change in marital state, affective disorder or schizophrenia	Pending litigation, receiving benefits at admission	Age, gender, family history of chronic illness, history of somatisation, psychiatric treatment, social class
Mace <sup>29</sup>	Motor	Early diagnosis	Age, use of non-psychotropic medication, anxiety > depression, personality disorder, many GP/outpatient/ hospital visits.	Alternative consultations, questionnaires of mood, illness behaviour
Couprie <sup>30</sup>	Motor	Early diagnosis, improvement during initial hospital stay	-	Age, preceding life event
Ljungberg <sup>35</sup>	Motor	-	Personality disorder	Age, gender, IQ

A limited amount of data support the idea that a good explanation of the diagnosis and patient confidence in the physician correlates with a good outcome for functional motor symptoms. Studies in functional motor symptoms are limited by the retrospective nature of the way in which this question was asked. SNSS found that beliefs about illness were of key importance in predicting outcome, more so than disability, symptom count and emotional distress which all disappeared from a multifactorial model. A review of prognostic factors in non-epileptic attacks did not find that understanding of the disorder makes a difference in outcome, but suggested that acceptance does: patients who showed relief that their diagnosis was not epilepsy had improved seizure frequency, whereas those who reacted with anger or confusion had a poorer outcome.

Includes factors which did not reach statistical significance.

### Limitations

The studies that matched our criteria were mostly retrospective, small and largely did not fulfil basic aspects of a proper follow-up study, with baseline measurement of prognostic factors or outcome of specific symptoms and proper follow-up rates. The data should therefore be interpreted with care. There is likely to be considerable heterogeneity between, for example, patients with short duration of symptoms attending a local service <sup>34</sup> and patients with fixed dystonia attending a tertiary centre. <sup>12</sup> The minimum follow-up duration of 6 months is relatively arbitrary. Patients who present acutely and remit in a few days will be missed. However, it is important to know whether

these patients relapse in the ensuing months, and therefore, a minimum follow-up duration seems necessary.

In addition follow-up rates were variable, patients with better outcomes may be more likely to be lost to follow-up. There were no treatment intervention studies in the review (those studies were excluded), but during the follow-up period, some of the studies described treatments. We found that the outcome of these studies was comparable to studies where treatment was not mentioned (crude weighted mean 49% vs 39% same or worse). It seems likely that even where treatment was not mentioned that many would have received some form of it so it remains hard to know what the 'untreated' natural history of functional motor symptoms might be. Our review was also limited in its scope to adult studies. There was a risk that by including paediatric studies, the data would not have been generalisable, since most neurologists are either adult or paediatric neurologists. The review was also limited by selecting only English Language Studies.

## **CONCLUSION**

Follow-up studies of functional motor symptoms give us some insights regarding outcome and prognostic factors but are limited by their largely retrospective and selective nature. Overall, the prognosis appears unfavourable. Based on the limited data available, there is a suggestion that a short duration, early diagnosis and an acceptable explanation would be valuable in clinical practice.

# **Neuropsychiatry**

The severity and chronicity of functional motor symptoms argues for the importance of larger prospective studies including multiple prognostic factors and comorbidity at baseline in order to better understand their natural history.

**Contributors** JG: substantial contributions to conception and design, acquisition of data, analysis and interpretation, wrote the first and last draft of the article. JS: substantial contributions to conception and design, acquisition of data, analysis and interpretation, critically revising, finally approved the version to be published. ME: substantial contribution to design, to interpretation of data, critically revised the manuscript, finally approved the version to be published. AC: substantial contribution to the concept and design, to interpretation of data, critically revised the manuscript, finally approved the version to be published.

#### Competing interests None.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data sharing statement** All data, abstracted from the included studies in this systematic review, are available to anyone being interested in receiving them.

#### **REFERENCES**

- 1 Edwards MJ, Bhatia KP. Functional (psychogenic) movement disorders: merging mind and brain. *Lancet Neurol* 2012;11:250–60.
- 2 Stone J, Warlow C, Sharpe M. The symptom of functional weakness: a controlled study of 107 patients. *Brain* 2010;133(Pt 5):1537–51.
- 3 Stone J, Carson A, Duncan R, et al. Who is referred to neurology clinics?—the diagnoses made in 3781 new patients. Clin Neurol Neurosurg 2010;112:747–51.
- 4 Lempert T, Dieterich M, Huppert D, et al. Psychogenic disorders in neurology: frequency and clinical spectrum. Acta Neurol Scand 1990;82:335–40.
- 5 Stone J, Smyth R, Carson A, et al. Systematic review of misdiagnosis of conversion symptoms and "hysteria". BMJ 2005:331:989.
- 6 Singh SP, Lee AS. Conversion disorders in Nottingham: alive, but not kicking. J Psychosom Res 1997;43:425–30.
- 7 Heruti RJ, Reznik J, Adunski A, et al. Conversion motor paralysis disorder: analysis of 34 consecutive referrals. Spinal Cord 2002;40:335–40.
- 8 Monday K. Jankovic J. Psychogenic myoclonus. *Neurology* 1993:43:349–52.
- Baker JH, Silver JR. Hysterical paraplegia. J Neurol Neurosurg Psychiatry 1987;50:375–82.
- 10 Koller W, Lang A, Vetere-Overfield B, et al. Psychogenic tremors. Neurology 1989;39:1094–9.
- 11 Apple DF Jr. Hysterical spinal paralysis. *Paraplegia* 1989;27:428–31.
- 12 Ibrahim NM, Martino D, van de Warrenburg BP, et al. The prognosis of fixed dystonia: a follow-up study. Parkinsonism Relat Disord 2009;15:592–7.
- 13 Schrag A, Trimble M, Quinn N, et al. The syndrome of fixed dystonia: an evaluation of 103 patients. Brain 2004;127:2360–72.
- 14 Jankovic J, Vuong KD, Thomas M. Psychogenic tremor: long-term outcome. CNS Spectr 2006;11:501–8.
- 15 Thomas M, Vuong KD, Jankovic J. Long-term prognosis of patients with psychogenic movement disorders. *Parkinsonism Relat Disord* 2006;12:382–7.
- 16 Carter AB. The prognosis of certain hysterical symptoms. BMJ 1949;1:1076–9.
- 17 Kim YJ, Pakiam AS, Lang AE. Historical and clinical features of psychogenic tremor: a review of 70 cases. Can J Neurol Sci 1999;26:190–5.
- 18 Lang AE, Koller WC, Fahn S. Psychogenic parkinsonism. *Arch Neurol* 1995;52:802–10.
- 19 Stone J, Sharpe M, Rothwell PM, et al. The 12 year prognosis of unilateral functional weakness and sensory disturbance. J Neurol Neurosurg Psychiatry 2003;74:591–6.
- 20 Crimlisk HL, Bhatia K, Cope H, et al. Slater revisited: 6 year follow up study of patients with medically unexplained motor symptoms. BMJ 1998;316:582–6.

- 21 Factor SA, Podskalny GD, Molho ES. Psychogenic movement disorders: frequency, clinical profile, and characteristics. J Neurol Neurosurg Psychiatry 1995:59:406–12.
- McKeon A, Ahlskog JE, Bower JH, et al. Psychogenic tremor: long-term prognosis in patients with electrophysiologically confirmed disease. Mov Disord 2009;24:72–6.
- 23 Deuschl G, Koster B, Lucking CH, et al. Diagnostic and pathophysiological aspects of psychogenic tremors. Mov Disord 1998;13:294–302.
- 24 Lang AE. Psychogenic dystonia: a review of 18 cases. Can J Neurol Sci 1995;22:136–43.
- 25 Munhoz RP, Zavala JA, Becker N, et al. Cross-cultural influences on psychogenic movement disorders—a comparative review with a Brazilian series of 83 cases. Clin Neurol Neurosurg 2011;113:115–18.
- 26 Ertan S, Uluduz D, Ozekmekci S, et al. Clinical characteristics of 49 patients with psychogenic movement disorders in a tertiary clinic in Turkey. Mov Disord 2009;24:759–62.
- 27 Feinstein A, Stergiopoulos V, Fine J, et al. Psychiatric outcome in patients with a psychogenic movement disorder: a prospective study. Neuropsychiatry Neuropsychol Behav Neurol 2001:14:169–76.
- 28 Knutsson E, Martensson A. Isokinetic measurements of muscle strength in hysterical paresis. Electroencephalogr Clin Neurophysiol 1985;61:370–4.
- 29 Mace CJ, Trimble MR. Ten-year prognosis of conversion disorder. Br J Psychiatry 1996:169:282–8.
- 30 Couprie W, Wijdicks E-FM, Rooijmans H-GM, et al. Outcome in conversion disorder: A follow-up study. J Neurol Neurosurg Psychiatry 1995;58:750–2.
- 31 Gatfield PD, Guze SB. Prognosis and differential diagnosis of conversion reactions. *Dis Nerv Sys* 1962;23:623–31.
- 32 Williams DT, Ford B, Fahn S. Phenomenology and psychopathology related to psychogenic movement disorders. Adv Neurol 1995;65:231–57.
- 33 Brown W, Pisetsky J. Sociopsychologic factors in hysterical paraplegia. *J Nerv Ment Dis* 1954;119:283–98.
- 34 Binzer M, Kullgren G. Motor conversion disorder. A prospective 2- to 5-year follow-up study. *Psychosomatics* 1998;39:519–27.
- 35 Ljungberg L. Hysteria: a clinical, prognostic and genetic study. Acta Psychiat Neurol Scand Suppl 1957;112:1–162.
- 36 Crimlisk HL, Bhatia KP, Cope H, et al. Patterns of referral in patients with medically unexplained motor symptoms. J Psychosom Res 2000;49:217–19.
- 37 Durrant J, Rickards H, Cavanna AE. Prognosis and outcome predictors in psychogenic nonepileptic seizures. *Epilepsy Research and Treatment* 2011:2011:274736.
- 38 Sharpe M, Stone J, Hibberd C, et al. Neurology out-patients with symptoms unexplained by disease: illness beliefs and financial benefits predict 1-year outcome. Psychol Med 2009;23:1–10.
- 39 Anderson KE, Gruber-Baldini AL, Vaughan CG, et al. Impact of psychogenic movement disorders versus Parkinson's on disability, quality of life, and psychopathology. Mov Disord 2007;22:2204–9.
- 40 Carson A, Stone J, Hibberd C, et al. Disability, distress and unemployment in neurology outpatients with symptoms 'unexplained by organic disease'. J Neurol Neurosurg Psychiatry 2011;82:810–13.
- Pehlivanturk B, Unal F. Conversion disorder in children and adolescents: a 4-year follow-up study. J Psychosom Res 2002;52:187–91.
- 42 Ani C, Reading R, Lynn R, et al. Incidence and 12-month outcome of non-transient childhood conversion disorder in the UK and Ireland. Br J Psychiatry 2013:202:413–18
- 43 Schwingenschuh P, Pont-Sunyer C, Surtees R, et al. Psychogenic movement disorders in children: a report of 15 cases and a review of the literature. Mov Disord 2008:23:1882–8.
- 44 Wassmer E, Wright E, Rideout S, et al. Idiopathic gait disorder among in-patients with acquired gait disorders admitted to a children's hospital. Pediatr Rehabil 2002:5:21–8.